

Comorbidity of Generalized Anxiety Disorder and Substance Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions

Analucía A. Alegría, BS; Deborah S. Hasin, PhD; Edward V. Nunes, MD; Shang-Min Liu, MS; Carrie Davies, BA; Bridget F. Grant, PhD; and Carlos Blanco, MD, PhD

Objective: Prior research has consistently documented a strong association between generalized anxiety disorder (GAD) and substance use disorder (SUD). Comorbidity of GAD and SUD (GAD-SUD) represents clinical challenges, as the patients' symptoms are often more severe and are frequently prolonged, making their management more complex when compared with individuals with GAD only. The purpose of this study was to examine whether individuals with GAD-SUD differ meaningfully from individuals with GAD and no SUD comorbidity (GAD-NSUD) in terms of demographic characteristics, risk factors, psychiatric comorbidity, and clinical correlates.

Method: Data were derived from the 2001–2002 National Epidemiologic Survey on Alcohol and Related Conditions (N = 43,093). Diagnoses were made using the Alcohol Use Disorder and Associated Disabilities Interview Schedule–*DSM-IV* Version.

Results: We found that the lifetime prevalence rate of GAD-SUD is about 2.04%, while that of GAD-NSUD is 2.10%. Individuals with GAD-SUD showed higher psychiatric comorbidity rates than those with GAD-NSUD. Treatment-seeking rates for GAD are equally low in individuals with GAD-SUD and GAD-NSUD. Both groups were as likely to receive pharmacologic treatment for anxiety.

Conclusions: The findings of our study indicate that individuals with GAD-SUD constitute half of the lifetime prevalence of GAD and that GAD-SUD is associated with high overall vulnerability for additional psychopathology, particularly in the externalizing spectrum; higher disability; and higher use of alcohol and drugs to relieve anxiety symptoms.

J Clin Psychiatry 2010;71(9):1187–1195

© Copyright 2010 Physicians Postgraduate Press, Inc.

Generalized anxiety disorder has a 12-month prevalence of 1%–2.1% and a lifetime prevalence of 2.8%–4.1% in Europe and in the United States^{1,2}; is chronic and disabling; and is associated with high rates of psychiatric comorbidity^{1–3} and substantial personal, societal, and economic costs.^{4–6}

Prior research has consistently documented a strong association between GAD and substance use disorder (SUD).^{7–9} High rates of comorbidity of GAD and SUD have been frequently reported in clinical^{10–14} and community samples^{8,15–22} and have been associated with worse outcomes than their single-diagnosis counterparts. Among individuals with alcohol use disorders, those with comorbid anxiety are more disabled,¹ drink more heavily,^{23,24} have worse social adjustment and outcome,^{8,25} have a greater number of hospitalizations, and have a greater severity of psychiatric illness as compared with those with alcohol use disorders only. A long-term follow-up study²⁶ found that comorbid SUD among individuals with GAD significantly decreased the likelihood of recovery from GAD and significantly increased the risk of recurrence of this disorder. Thus, GAD and SUD comorbidity (GAD-SUD) represents clinical challenges, as the patients' symptoms are often more severe and are frequently prolonged, making their management more complex.

Despite the obvious differences in symptom presentation, course, and treatment response across different anxiety disorders, a number of research studies examining the correlates of comorbid SUD and anxiety have considered anxiety disorders as a single, unitary entity,^{23,24,27,28} whereas only a few studies have looked at the association of SUD and GAD as a specific type of anxiety disorder.^{25,29–31} Furthermore, prior studies of the comorbidity of SUD and GAD often relied upon treatment-seeking samples and focused almost exclusively on alcohol use disorders.^{25,29–31}

In view of the limitations of prior research, we sought to fill this gap in knowledge, examining whether individuals with GAD-SUD differ meaningfully from individuals with GAD and no SUD comorbidity (GAD-NSUD) in terms of demographic characteristics, risk factors, psychiatric comorbidity, and clinical correlates in a nationally representative sample of individuals of the United States, as assessed in the National Institute on Alcohol Abuse and Alcoholism (NIAAA) 2001–2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Specifically, we sought to (1) examine the prevalence of GAD-SUD and GAD-NSUD and their

Submitted: May 4, 2009; accepted August 14, 2009.

(doi:10.4088/JCP.09m05328gry).

Corresponding author: Bridget F. Grant, PhD, Laboratory of Epidemiology and Biometry, Division of Intramural Clinical and Biological Research, National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, MS 9304, 5635 Fishers Lane, Bethesda, MD 20892-9304 (bgrant@willco.niaaa.nih.gov).

Generalized anxiety disorder (GAD) is characterized by excessive anxiety of at least 6 months' duration that is hard to control, not focused on a specific situation or objects, and not triggered by recent stressing events. Associated symptoms include restlessness, fatigue, concentration difficulties, irritability, muscle tension, and sleep disorders.

FOR CLINICAL USE

- ◆ Substance use disorders (SUDs) are prevalent conditions that affect half of individuals with generalized anxiety disorder (GAD). Those individuals represent the more severe cases of GAD.
- ◆ Individuals with GAD and a lifetime SUD have increased vulnerability for additional psychopathology.
- ◆ Several medications can be useful for treating anxiety symptoms in individuals with comorbid SUD. Clinicians should be cautious in the use of benzodiazepines for treating GAD and should conduct a thorough assessment for the presence of risk factors for SUD.

sociodemographic correlates, (2) estimate the prevalence of risk factors for anxiety disorders in individuals in those 2 groups, (3) compare the lifetime prevalence of psychiatric disorders in both groups of individuals, and (4) estimate rates and patterns of treatment-seeking in individuals with GAD-SUD and GAD-NSUD.

METHOD

National Epidemiologic Survey on Alcohol and Related Conditions Sample

The 2001–2002 NESARC is a survey of a representative sample of the United States conducted by NIAAA, as described elsewhere.^{16,32} The NESARC target population was individuals aged 18 years and over in the civilian non-institutional population residing in households and group quarters. The survey included those residing in the continental United States, District of Columbia, Alaska, and Hawaii. A total of 43,093 participants completed face-to-face personal interviews. Data were weighted to reflect design characteristics of the NESARC survey and to account for oversampling and nonresponse. The research protocol, including informed consent procedures, was approved by the US Census Bureau and the US Office of Management and Budget Institutional Review Board. All respondents provided written informed consent before they were interviewed.

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Diagnostic Assessment

The diagnostic interview used to generate diagnoses was the Alcohol Use Disorder and Associated Disabilities Interview Schedule–DSM-IV Version (AUDADIS-IV) from the NIAAA.³³ This structured diagnostic interview designed for lay interviewers was developed to advance measurement of substance use and mental disorders in large-scale surveys. The test-retest reliability and validity of AUDADIS-IV measures of DSM-IV disorders have been reported elsewhere.^{1,32,34–41}

Generalized Anxiety Disorder

DSM-IV GAD was diagnosed when excessive anxiety and worry about a number of events or activities were present more days than not for at least 6 months, accompanied by difficulty controlling the worry and at least 3 of the 6 DSM-IV GAD symptoms. Lifetime GAD was defined as

having at least 1 episode of GAD over the life course. Diagnoses of GAD also required that the DSM-IV clinical significance criterion be met; that is, symptoms of the disorder must have caused clinically significant distress or impairment. The DSM-IV GAD diagnosis excludes substance-induced episodes or episodes due to a medical condition. In differentiating substance-induced from independent disorders, AUDADIS-IV used specific questions about the chronological relationship between intoxication or withdrawal and the full anxiety syndrome.⁴² Specific questions about chronology improve the reliability and validity of GAD diagnoses in individuals who use psychoactive substances.^{43–45} As reported in detail elsewhere,^{38,46–49} test-retest reliability for GAD was fair ($\kappa=0.42$). We subdivided the sample of individuals with GAD between those with lifetime SUD comorbidity (GAD-SUD) and those with no lifetime SUD comorbidity (GAD-NSUD).

Mood and Anxiety Disorders

Other mood (depression, dysthymia, bipolar I, bipolar II) and anxiety (panic disorder with and without agoraphobia, social phobia, and specific phobia) diagnoses in this report are DSM-IV primary diagnoses. In DSM-IV, “primary” excludes mental disorders that are substance-induced or due to a medical condition.

All mood and anxiety disorders satisfied the DSM-IV clinical significance criterion. Test-retest reliabilities of AUDADIS-IV measures of DSM-IV mood and anxiety disorders were fair to good, ranging from $\kappa=0.42$ for specific phobia to $\kappa=0.62$ for major depression.^{32,36}

Substance Use Disorders

The questions of AUDADIS-IV operationalize DSM-IV criteria for alcohol- and drug-specific abuse and dependence for 10 drug classes (aggregated in this report).¹⁶ Consistent with the DSM-IV, lifetime AUDADIS-IV diagnoses of alcohol abuse required at least 1 of the 4 criteria for abuse either in the 12-month period preceding the interview or previously. The AUDADIS-IV alcohol dependence diagnoses required at least 3 of the 7 DSM-IV criteria for dependence during the past year or prior. For prior diagnoses of alcohol dependence, at least 3 criteria must have occurred within a 1-year period, following the DSM-IV. Drug abuse and dependence and nicotine dependence diagnoses used the same algorithms.³¹ The test-retest reliabilities of AUDADIS-IV alcohol and drug disorders measures were excellent, exceeding

$\kappa = 0.74$ for alcohol diagnoses and $\kappa = 0.79$ for drug diagnoses.^{34,36,38,46–50} The discriminant and convergent,^{38,46,49–52} concurrent,^{37,53} construct,^{49,54} and population validity of the AUDADIS-IV alcohol and drug use disorder diagnoses also have been well documented.

Personality Disorders

The AUDADIS-IV assessments of *DSM-IV* personality disorders have been presented previously.^{35,55} They include avoidant, dependent, obsessive-compulsive, paranoid, schizoid, histrionic, and antisocial personality disorders. The *DSM-IV* personality disorder diagnoses require evaluating long-term patterns of functioning. The AUDADIS-IV personality disorder diagnoses were made accordingly. To receive a *DSM-IV* personality disorder diagnosis, respondents needed to endorse the required number of *DSM-IV* symptom items for the specific personality disorder, with at least 1 symptom causing distress or social or occupational dysfunction. The reliability of AUDADIS-IV categorical diagnoses and dimensional scales of each personality disorder was assessed in a test-retest study as part of the NESARC survey proper.³² The reliability of the personality disorders in the community samples ranged from fair to good, from $\kappa = 0.40$ for histrionic personality disorder to $\kappa = 0.67$ for antisocial personality disorder.

Lifetime Risk Factors

Consistent with previous research,⁵⁶ this study included variables that addressed the etiologic complexity of internalizing disorders and are known risk factors for anxiety. The risk constructs specified were as follows: predisposing genetic influences,⁵⁷ such as (1) family history of depression, (2) family history of alcohol or drug problems, and (3) family history of problem behavior, and childhood risk factors, such as (1) parental loss due to death before age 18 years; (2) early-onset anxiety, operationalized as onset of any anxiety disorder before age 18 years; and (3) conduct disorder, operationalized as childhood conduct problems. We also examined the following 3 adult risk measures that have featured prominently in the literature on anxiety^{58,59}: (1) being divorced, measured by a self-report of history of a divorce; (2) stressful life events, measured with 12 items from the Social Readjustment Rating Scale (eg, fired from a job, forced to move)⁶⁰; and (3) history of trauma and victimization in the past 12 months, assessed by self-report of having personally been the victim of a crime or attempted crime, such as being beaten up, mugged, or attacked by a stranger or someone the person knew.

Other Measures

Age at onset, number of episodes, duration of only or longest (if applicable) episode, use of alcohol or drugs to help relieve symptoms of GAD, treatment utilization, and age at first treatment were ascertained among respondents with lifetime GAD. Additional questions about overall health status were assessed by self-report. Twelve-month disability was assessed using the mental health scale, the physical functioning scale, the social functioning scale, the role-emotional

scale, and component summary scores of the Medical Outcomes Study 12-Item Short-Form Health Survey, version 2 (SF-12v2),^{61,62} a reliable and valid impairment measure commonly used in population surveys. Respondents were classified as receiving treatment for GAD or SUD if they ever (1) visited a counselor, therapist, physician, or psychologist; (2) were a patient in a hospital for at least 1 night; (3) visited an emergency room; or (4) were prescribed medications.

Statistical Analyses

Weighted percentages and means were computed to derive prevalence, sociodemographic and clinical characteristics, and risk factors of respondents with GAD with and without comorbid SUD. A set of logistic regression analyses yielded odds ratios (ORs) indicating measures of association between GAD-NSUD and GAD-SUD and lifetime comorbid psychiatric disorders, risk factors, and clinical characteristics. Odds ratios were further adjusted (AOR) for those sociodemographic characteristics of the sample that were significantly different between the groups at a univariate level of analysis. Analyses were estimated using Software for Survey Data Analysis,⁶³ a software package that uses Taylor series linearization to adjust for the design effects of complex sample surveys like the NESARC.

RESULTS

Prevalence and Sociodemographic Correlates

Table 1 shows the prevalence and sociodemographic correlates of individuals with lifetime GAD-NSUD and GAD-SUD. Individuals with GAD-SUD were significantly more likely than individuals with GAD-NSUD to be male, to be US-born, to be in the 2 highest income groups, and to have a family income of \$20,000–\$34,000. Individuals with GAD-SUD were significantly less likely to be black, to be 45 years and older, and to live in the South than individuals with GAD-NSUD.

Lifetime Risk Factors

Lifetime prevalence of risk factors among individuals with GAD-SUD and GAD-NSUD are shown in Table 2. In the unadjusted models, individuals with GAD-SUD were more likely than those with GAD-NSUD to have a higher prevalence of family history of AUD/SUD and family history of problem behavior, as shown by unadjusted ORs. Individuals with GAD-SUD also had significantly higher prevalence of ever being divorced and history of victimization than those with GAD-NSUD.

When the ORs were adjusted for sociodemographic characteristics, individuals with GAD-SUD continued to be more likely than those with GAD-NSUD to have a higher prevalence of family history of AUD/SUD, family history of problem behavior, parental loss, and ever being divorced, while differences on the prevalence of history of victimization lost significance. Furthermore, individuals with GAD-SUD showed significantly lower prevalence of early-onset anxiety than those with GAD-NSUD.

Table 1. Sociodemographic Correlates of Individuals With GAD-SUD and GAD-NSUD

Characteristic	GAD-NSUD (n = 918) ^a		GAD-SUD (n = 839)		OR (95% CI)
	%	SE	%	SE	
Sex					
Male	19.90	1.68	45.81	2.17	3.40 (2.59–4.47)
Female	80.10	1.68	54.19	2.17	1.00 (1.00–1.00)
Race/ethnicity					
White	76.21	1.96	81.80	1.81	1.00 (1.00–1.00)
Black	9.86	1.06	6.30	0.91	0.60 (0.41–0.86)
Asian	2.38	0.62	4.08	0.97	1.60 (0.81–3.15)
Native American	2.69	0.74	1.36	0.58	0.47 (0.17–1.32)
Hispanic	8.88	1.39	6.46	1.15	0.68 (0.44–1.05)
US-born					
Yes	88.01	1.63	96.33	0.81	3.57 (2.26–5.63)
No	11.99	1.63	3.67	0.81	1.00 (1.00–1.00)
Age, y					
18–29	15.02	1.41	18.64	1.79	1.00 (1.00–1.00)
30–44	28.02	2.01	40.38	2.18	1.16 (0.81–1.67)
45–64	41.04	2.01	36.77	1.98	0.72 (0.53–0.99)
65+	15.92	1.24	4.22	0.79	0.21 (0.13–0.34)
Education					
< High school	14.81	1.34	13.13	1.44	0.82 (0.59–1.16)
High school	31.50	2.06	29.16	2.04	0.86 (0.65–1.15)
College	53.69	2.16	57.71	2.17	1.00 (1.00–1.00)
Individual income					
< \$20,000	57.08	2.16	47.38	2.08	1.00 (1.00–1.00)
\$20,000–\$34,999	20.48	1.65	22.12	1.59	1.30 (0.96–1.76)
\$35,000–\$70,000	17.99	1.74	23.43	1.66	1.57 (1.17–2.10)
> \$70,000	4.45	0.95	7.07	1.05	1.91 (1.13–3.25)
Family income					
< \$20,000	28.92	1.73	26.01	1.93	1.00 (1.00–1.00)
\$20,000–\$34,999	17.58	1.34	22.40	1.76	1.42 (1.02–1.96)
\$35,000–\$70,000	31.93	2.04	31.99	2.28	1.11 (0.80–1.54)
> \$70,000	21.56	2.13	19.61	1.73	1.01 (0.71–1.43)
Marital status					
Married	56.61	1.92	53.16	2.09	1.00 (1.00–1.00)
Widowed/separated/ divorced	28.30	1.58	28.75	1.78	1.08 (0.83–1.40)
Never married	15.09	1.31	18.09	1.67	1.28 (0.95–1.72)
Urbanicity					
Urban	78.71	2.12	77.84	2.52	1.00 (1.00–1.00)
Rural	21.29	2.12	22.16	2.52	1.05 (0.80–1.39)
Region					
Northeast	17.57	3.71	15.80	2.62	0.72 (0.48–1.09)
Midwest	26.15	3.23	29.90	3.61	0.92 (0.68–1.25)
South	34.86	3.41	27.66	3.06	0.64 (0.47–0.87)
West	21.42	3.27	26.65	3.92	1.00 (1.00–1.00)
Insurance					
Private	53.47	1.85	56.45	2.11	1.00 (1.00–1.00)
Public	28.52	1.65	23.80	1.81	0.79 (0.61–1.02)
No insurance	18.02	1.56	19.75	1.66	1.04 (0.78–1.39)

^aReference group.

Abbreviations: GAD-NSUD = generalized anxiety disorder and no substance use disorder comorbidity, GAD-SUD = generalized anxiety disorder and substance use disorder comorbidity.

Psychiatric Comorbidity

Table 3 shows the lifetime prevalence of Axis I and II disorders among individuals with GAD-SUD and with GAD-NSUD. In the unadjusted models, individuals with GAD-SUD were significantly more likely than those individuals with GAD-NSUD to have a lifetime history of any psychiatric disorder, any Axis I disorder, nicotine dependence, bipolar I and II disorder, any anxiety disorder, panic disorder, social anxiety disorder, pathological gambling, any personality disorder, paranoid disorder, histrionic personality disorder, and antisocial personality disorder. Individuals

with GAD-SUD were less likely than those with GAD-NSUD to have a lifetime history of major depressive disorder.

When the ORs were adjusted for sociodemographic characteristics, individuals with GAD-SUD continued to be more likely than those with GAD-NSUD to have a lifetime history of any psychiatric disorder, any Axis I disorder, nicotine dependence, bipolar I and II disorder, any anxiety disorder, panic disorder, pathological gambling, and antisocial personality disorder, but differences on the prevalence of social anxiety disorder, any personality disorder, paranoid personality disorder, and histrionic personality disorder failed to reach significance. Individuals with GAD-SUD continued to be less likely than those with GAD-NSUD to have a lifetime history of major depressive disorder.

Clinical Characteristics of Generalized Anxiety Disorder

Table 4 shows the differences in clinical characteristics among individuals with GAD-NSUD and with GAD-SUD. Individuals with GAD-SUD were more likely than those with GAD-NSUD to present difficulty concentrating, have arguments with friends or relatives, and have difficulty completing daily tasks.

When the ORs were adjusted for sociodemographic characteristics, individuals with GAD-SUD continued to be significantly more likely to report difficulty concentrating than those with GAD-NSUD, and the prevalence of associated cardiovascular and respiratory symptoms became significantly higher among those with GAD-SUD than those with GAD-NSUD, whereas differences in the prevalence of arguments with friends or relatives and difficulty completing daily tasks lost significance. In these adjusted models, individuals with GAD-SUD were more likely to have lower scores on the mental health component summary, social functioning, and mental health scales of the SF-12v2 than those with GAD-NSUD.

Age at Onset, Course, and Treatment-Seeking and Self-Medication Characteristics

Age at onset, course, and treatment-seeking and self-medication characteristics among individuals with GAD-SUD and GAD-NSUD are shown in Table 5. Individuals with GAD-SUD had a mean age at onset for GAD of 30.45 years with a mean age at first treatment of 32.47 years, whereas individuals with GAD-NSUD had a mean age at onset of 34.90 years with a mean age at first treatment of 36.99 years. In the unadjusted models, individuals with GAD-SUD were more likely to have an earlier age at onset of GAD and an earlier age at first treatment of GAD and to use alcohol and drugs to relieve GAD symptoms.

In models adjusted for sociodemographic characteristics, age at onset of GAD and age at first treatment for GAD did not differ significantly between individuals with GAD-SUD and those with GAD-NSUD. Individuals with GAD-SUD continued to be significantly more likely than individuals with GAD-NSUD to use alcohol and drugs to relieve GAD symptoms. GAD treatment-seeking rates in the 2 groups were low and did not differ significantly.

Table 2. Prevalence of Generalized Anxiety Disorder Risk Factors Among Individuals With GAD-NSUD and GAD-SUD

Risk Factor	GAD-NSUD (n=918) ^a		GAD-SUD (n=839)		OR (95% CI)	AOR ^b (95% CI)
	%	SE	%	SE		
Family history of depression	68.25	1.84	70.45	1.91	1.11 (0.87–1.42)	1.09 (0.83–1.43)
Family history of AUD/SUD	52.33	1.86	66.61	1.87	1.82 (1.47–2.25)	2.06 (1.59–2.67)
Family history of problem behavior	35.88	1.82	47.22	1.95	1.60 (1.29–1.98)	1.65 (1.30–2.08)
Parental loss before 18 y	11.13	1.19	10.40	1.44	0.93 (0.62–1.39)	0.98 (0.62–1.53)
Early onset of anxiety disorder before 18 y	64.83	1.88	61.73	1.96	0.88 (0.71–1.08)	0.75 (0.58–0.96)
Conduct disorder before 15 y	1.46	0.57	1.69	0.46	1.16 (0.44–3.07)	0.87 (0.33–2.31)
Ever divorced	28.45	2.02	44.28	2.20	2.00 (1.53–2.61)	2.32 (1.71–3.15)
Low self-esteem	31.31	1.95	33.27	2.22	1.09 (0.84–1.42)	1.02 (0.75–1.37)
History of victimization	5.64	1.03	9.38	1.11	1.73 (1.09–2.75)	1.56 (0.92–2.63)

^aReference group. ^bAdjusted odds ratio (AOR) is adjusted for sex, race/ethnicity, US-born, age, individual income, family income, and region.

Abbreviations: AUD = alcohol use disorder, GAD-NSUD = generalized anxiety disorder and no substance use disorder comorbidity, GAD-SUD = generalized anxiety disorder and substance use disorder comorbidity.

Table 3. Lifetime Prevalence of Axis I and Axis II Disorders in Individuals With GAD-NSUD and GAD-SUD

Psychiatric Comorbidity	GAD-NSUD (n=918) ^a		GAD-SUD (n=839)		OR (95% CI)	AOR ^b (95% CI)
	%	SE	%	SE		
Any psychiatric disorder ^c	89.99	1.14	94.29	1.14	1.84 (1.13–3.00)	1.64 (1.04–2.58)
Any Axis I disorder	85.58	1.26	92.94	1.20	2.22 (1.44–3.41)	2.10 (1.39–3.18)
Alcohol use disorder	0.00	0.00	92.68	1.19
Alcohol abuse	0.00	0.00	38.55	1.99
Alcohol dependence	0.00	0.00	54.13	1.91
Drug use disorder	0.00	0.00	46.59	2.30
Drug abuse	0.00	0.00	24.15	1.81
Drug dependence	0.00	0.00	22.44	2.09
Nicotine dependence	18.71	1.52	54.04	2.42	5.11 (3.86–6.75)	4.83 (3.68–6.36)
Mood disorder	70.63	1.74	74.47	2.02	1.21 (0.92–1.59)	1.24 (0.93–1.65)
Major depressive disorder	52.77	1.98	42.85	2.10	0.67 (0.53–0.85)	0.68 (0.53–0.88)
Bipolar I	11.91	1.21	23.19	1.88	2.23 (1.65–3.03)	2.11 (1.51–2.96)
Bipolar II	3.36	0.76	6.77	1.11	2.09 (1.19–3.65)	2.19 (1.27–3.77)
Dysthymia	19.59	1.70	18.55	1.58	0.93 (0.69–1.26)	1.01 (0.73–1.40)
Any anxiety disorder ^d	53.87	2.02	61.44	2.12	1.36 (1.08–1.72)	1.34 (1.04–1.72)
Panic disorder	23.45	1.70	34.61	1.94	1.73 (1.34–2.23)	1.80 (1.35–2.40)
Social anxiety disorder	25.19	1.83	30.83	1.96	1.32 (1.02–1.71)	1.17 (0.87–1.57)
Specific phobia	33.63	2.11	38.02	1.92	1.21 (0.94–1.55)	1.25 (0.95–1.64)
Conduct disorder	1.46	0.57	1.69	0.46	1.16 (0.44–3.07)	0.87 (0.33–2.31)
Pathological gambling	0.40	0.20	1.91	0.56	4.84 (1.51–5.51)	5.42 (1.49–19.63)
Psychotic disorder	1.33	0.33	1.91	0.54	1.44 (0.68–3.05)	1.06 (0.46–2.45)
Any personality disorder	47.15	1.97	57.54	2.26	1.52 (1.21–1.90)	1.19 (0.92–1.55)
Avoidant	15.09	1.58	19.12	1.92	1.33 (0.94–1.88)	1.00 (0.66–1.50)
Dependent	3.48	0.72	5.58	1.24	1.64 (0.90–2.98)	1.82 (0.96–3.44)
Obsessive-compulsive	27.66	1.95	30.75	2.06	1.16 (0.90–1.50)	0.94 (0.70–1.25)
Paranoid	21.45	1.74	27.85	1.89	1.41 (1.06–1.89)	1.38 (0.98–1.95)
Schizoid	14.09	1.40	17.42	1.71	1.29 (0.92–1.79)	1.26 (0.88–1.79)
Histrionic	6.55	0.96	10.36	1.47	1.65 (1.09–2.48)	1.47 (0.93–2.30)
Antisocial	3.07	0.74	19.36	1.62	7.58 (4.45–2.91)	5.62 (3.25–9.72)

^aReference group. ^bAdjusted odds ratio (AOR) is adjusted for sex, race/ethnicity, US-born, age, individual income, family income, and region. ^cAny psychiatric disorder does not include alcohol use disorder, drug use disorder, and generalized anxiety disorder. ^dAny anxiety disorder does not include generalized anxiety disorder.

Abbreviations: GAD-NSUD = generalized anxiety disorder and no substance use disorder comorbidity, GAD-SUD = generalized anxiety disorder and substance use disorder comorbidity. Symbol: ... = not applicable.

Age at onset and treatment patterns of SUD among individuals with GAD-SUD were also obtained. Individuals with GAD-SUD had a mean age at onset for SUD of 21.25 years with a mean age at first treatment of 28.24 years. Among individuals with GAD-SUD, 18.20% were treated for SUD as outpatients, 16.00% were treated as inpatients,

and 8.55% reported emergency room admittance.

DISCUSSION

This is the first epidemiologic study to report the prevalence of the joint comorbidity of GAD with SUD and to compare the prevalence and sociodemographic and clinical characteristics among individuals with GAD with and without comorbid SUD (ie, GAD-SUD and GAD-NSUD) in a nationally representative sample of the general population. We found that (1) the lifetime prevalence of GAD-SUD is about 2.04%, while that of GAD-NSUD is 2.10%; (2) individuals with GAD-SUD showed higher psychiatric comorbidity rates than those with GAD-NSUD; and (3) treatment-seeking rates for GAD are equally low in GAD-SUD and GAD-NSUD groups.

Our study found that GAD-SUD has a higher prevalence (2.04%) than other anxiety disorders widely recognized as important and disabling, such as obsessive-compulsive disorder (1.6%),⁶⁴ and other Axis I disorders, such as schizophrenia. Consistent with the strong association between these 2 disorders previously described,^{7,8} almost 50% of individuals with lifetime GAD in the NESARC had a comorbid lifetime SUD. Three converging sets of factors may partially help to explain this high rate of comorbidity. First, our study found significantly higher prevalence of family history of antisocial behavior and family history of alcohol and drug use disorders among those with GAD-SUD, suggesting that risk factors for psychopathology may play a stronger role in the onset of GAD-SUD than in GAD-NSUD. Second, the onset of SUD preceded the onset of GAD among those with GAD-SUD, suggesting that SUD, at least in some cases, may facilitate the initiation of GAD. Third, individuals with GAD-SUD had significantly higher rates of use of alcohol and drugs to relieve symptoms of anxiety than those with GAD-NSUD, a behavior

that may provide temporary relief for the anxiety symptoms but often leads to their long-term maintenance. Taken together, these findings suggest a stronger predisposition for psychopathology among individuals with GAD-SUD that is further exacerbated by the use of substances. From the treatment point of view, these findings suggest caution in

Table 4. Prevalence of Criteria and Clinical Characteristics of Individuals With GAD-NSUD and GAD-SUD

GAD Clinical Symptoms and Correlates	GAD-NSUD (n = 918) ^a		GAD-SUD (n = 839)		Wald F	P Value	Wald F	P Value
	Mean	SE	Mean	SE				
Number of criteria	4.94	0.04	4.94	0.04	0.00	.9966	0.33	.5684
Diagnostic criteria	%	SE	%	SE	OR	95% CI	AOR ^b	95% CI
Restlessness or feeling keyed up or on edge	92.45	1.20	92.42	1.07	1.00	(0.61–1.63)	0.97	(0.59–1.59)
Being easily fatigued	84.18	1.41	80.93	1.51	0.80	(0.60–1.05)	0.92	(0.67–1.26)
Difficulty concentrating or mind going blank	90.05	1.22	93.28	0.99	1.53	(1.01–2.33)	1.75	(1.11–2.77)
Irritability	83.49	1.54	86.85	1.59	1.31	(0.92–1.86)	1.27	(0.87–1.85)
Muscle tension	63.73	2.14	61.74	1.99	0.92	(0.71–1.19)	1.04	(0.79–1.35)
Sleep disturbance	80.46	1.47	79.21	1.90	0.93	(0.70–1.23)	0.87	(0.65–1.18)
Associated clinical characteristics								
Associated autonomic symptoms	68.42	2.02	70.31	1.85	1.09	(0.85–1.40)	1.30	(0.98–1.72)
Associated cardiovascular symptoms	42.61	1.99	47.89	2.00	1.24	(0.99–1.55)	1.33	(1.04–1.71)
Associated respiratory symptoms	40.94	2.10	44.84	2.01	1.17	(0.93–1.47)	1.34	(1.04–1.74)
Associated gastrointestinal symptoms	55.34	2.07	55.12	2.03	0.99	(0.78–1.26)	1.10	(0.83–1.45)
Urinary symptoms	30.34	1.67	30.29	2.06	1.00	(0.78–1.28)	1.20	(0.90–1.58)
Arguments or friction with relatives or friends	57.82	1.93	64.53	2.21	1.33	(1.04–1.69)	1.03	(0.80–1.32)
Difficulty or inability to complete daily tasks	73.91	1.78	78.76	1.74	1.31	(1.00–1.72)	1.30	(0.98–1.73)
Restrict usual activities	53.73	2.11	56.76	2.25	1.13	(0.88–1.45)	1.14	(0.87–1.48)
	Mean	SE	Mean	SE	Wald F	P Value	Wald F	P Value
Number of stressful situations in last 12 months	7.07	0.24	7.38	0.24	0.95	.3472	0.06	.8126
SF-12v2 scores								
Physical health component summary	47.21	0.53	48.33	0.57	1.45	.1532	1.16	.2850
General health scale	44.70	0.55	45.35	0.60	0.81	.4200	1.22	.2738
Physical functioning scale	47.97	0.53	46.89	0.50	1.51	.1350	2.39	.1271
Role-physical scale	46.27	0.50	47.38	0.51	1.61	.1111	1.07	.3045
Bodily pain	44.41	0.59	44.66	0.51	–0.33	.7425	3.87	.0534
Mental health component summary	43.29	0.49	42.22	0.56	1.38	.1734	5.41	.0231
Social functioning scale	44.66	0.56	43.78	0.58	1.09	.2786	5.51	.0220
Role-emotional scale	43.20	0.51	43.07	0.65	0.15	.8838	3.55	.0641
Mental health scale	42.83	0.47	42.06	0.55	1.05	.2965	5.17	.0263
Overall health	%	SE	%	SE	OR	95% CI	AOR ^b	95% CI
Excellent to good	70.19	1.72	72.31	1.91	1.11	(0.87–1.42)	0.89	(0.66–1.21)
Fair to poor	29.81	1.72	27.69	1.91	1.00	(1.00–1.00)	1.00	(1.00–1.00)

^aReference group. ^bAdjusted odds ratio (AOR) is adjusted for sex, race/ethnicity, US-born, age, individual income, family income, and region.

Abbreviations: GAD-NSUD = generalized anxiety disorder and no substance use disorder comorbidity, GAD-SUD = generalized anxiety disorder and substance use disorder comorbidity, SF-12v2 = Medical Outcomes Study 12-Item Short-Form Health Survey, version 2.

the use of benzodiazepines in individuals with GAD-SUD due to the increased risk for dependence of prescription drugs among individuals with SUD.⁶⁵ Antidepressants (eg, selective serotonin reuptake inhibitors), many of which are effective for GAD, may be preferable as first-line treatment for most individuals with GAD-SUD.⁶⁶

An alternative explanation for the high comorbidity between GAD and SUD would be to postulate the existence of an underlying (ie, latent) process that can cause both disorders but that sometimes manifests only 1 disorder, depending on the genetic and environmental factors of each individual. Future studies investigating the existence of genetic, neuroimaging, longitudinal course, or treatment response differences between GAD-SUD and GAD-NSUD may help discriminate between these 2 competing explanations.

Our study found a higher prevalence of psychiatric comorbidity (other than SUD) in individuals with GAD-SUD than in those with GAD-NSUD, further suggesting that the former is associated with a general vulnerability to psychopathology and to its exacerbation, especially to externalizing spectrum disorders.⁶⁷ In this line, we found a considerably high rate (30%) of lifetime bipolar disorder among those with GAD-SUD, a finding that extends those reported in

epidemiologic studies regarding the strong association between bipolar, substance use, and anxiety disorders.^{39,68} This subgroup of bipolar individuals is more likely to suffer from a more severe psychopathology and burden, since the comorbidity of anxiety disorders and SUD in bipolar individuals has been consistently associated with worse prognosis and higher rates of suicide attempts.^{69–72} A recent study investigating use of self-medication among individuals with mood disorders found that the highest prevalence of self-medication was seen in bipolar I disorder (41.0%) and that, after adjusting for the effects of substance use disorders, self-medication was associated with higher odds of comorbid anxiety.⁷³ This suggests that in a considerable number of cases of bipolar disorder, the comorbidity with anxiety and substance use disorders may be explained by the self-medication hypothesis.

The lower prevalence of major depressive disorder in the GAD-SUD group than in the GAD-NSUD group appears to be a direct result of the high prevalence of bipolar disorder in the GAD-SUD group. Because a diagnosis of bipolar disorder precludes a diagnosis of major depressive disorder, only 70.04% of individuals with GAD-SUD (ie, those without bipolar disorder) could meet a *DSM-IV*

Table 5. Age at Onset, Course, and Treatment Patterns of Individuals with GAD-NSUD and GAD-SUD

Characteristic	GAD-NSUD (n = 918) ^a		GAD-SUD (n = 839)		Wald <i>F</i>	<i>P</i> Value	Wald <i>F</i>	<i>P</i> Value
	Mean	SE	Mean	SE				
Generalized anxiety disorder								
Age at onset, y	34.90	0.66	30.45	0.55	5.53	<.0001	0.55	.4616
No. of GAD episodes	3.12	0.27	3.73	0.48	1.10	.2755	0.88	.3523
Duration of longest episode, mo ^b	11.53	0.01	11.76	0.02				
Age at first treatment, y	36.99	0.79	32.47	0.69	4.39	<.0001	1.58	.2132
Time from onset to first treatment, y	2.16	0.32	2.45	0.37	0.58	.5622	0.37	.5459
	%	SE	%	SE	OR	95% CI	AOR ^c	95% CI
Treated as outpatient	39.22	1.89	41.28	2.03	1.09	(0.86–1.37)	1.18	(0.91–1.53)
Treated as inpatient	6.05	0.93	8.36	1.22	1.42	(0.90–2.22)	1.37	(0.88–2.12)
Use of prescribed medication	34.79	1.94	37.50	2.16	1.12	(0.88–1.43)	1.18	(0.90–1.56)
Emergency room admittance	5.42	0.89	8.03	1.19	1.52	(0.94–2.48)	1.78	(1.06–3.00)
Use of alcohol to help relieve GAD symptoms	6.89	1.03	31.56	1.99	6.23	(4.34–8.94)	5.57	(3.76–8.24)
Substance use to help relieve GAD symptoms	0.91	0.33	13.58	1.48	17.06	(8.05–36.1)	14.35	(6.48–31.76)
Substance use disorder			Mean	SE				
Age at onset, y	21.25	0.33
Age at first treatment, y	28.24	0.84
			%	SE				
Treated as outpatient	18.20	1.61
Treated as inpatient	16.00	1.58
Emergency room admittance	8.55	1.17

^aReference group. ^bMedian calculated instead of mean. ^cAdjusted odds ratio (AOR) is adjusted for sex, race/ethnicity, US-born, age, individual income, family income, region, and insurance. Abbreviations: GAD-NSUD = generalized anxiety disorder and no substance use disorder comorbidity, GAD-SUD = generalized anxiety disorder and substance use disorder comorbidity. Symbol: ... = not applicable.

diagnosis of major depressive disorder, whereas 84.73% in the GAD-NSUD group could. Recalculation of the prevalence of major depressive disorder in these restricted groups yielded a prevalence of 62.28% (95% CI, 58.27–66.29) in the GAD-SUD group exclusive of bipolar disorder and 61.18% (95% CI, 56.11–66.25) in the GAD-NSUD after excluding bipolar disorders from that group, yielding an OR = 0.95 (95% CI, 0.72–1.27). Thus, after excluding individuals with bipolar disorder, the prevalence of major depressive disorder was similar in both groups. In individuals with GAD, comorbidity with SUD seems to increase the burden of mood disorders, mainly through an increase in the rates of bipolar disorder.

In addition, although we found that SUD was a marker of greater severity and disability in individuals with GAD, as assessed by statistically significant lower SF-12v2 scores in the mental health scale, social functioning scale, and mental health component summary, the difference between mean scores is somewhat small. The lack of differences between GAD individuals with and without comorbid SUD may be partially explained by a somewhat successful decrease in anxiety levels through self-medication, at the least in the short term.¹ Longitudinal studies are necessary to investigate the long-term impact of SUD on quality of life in individuals with GAD.

Our study found no differences in the rates of treatment-seeking for GAD between those with GAD-SUD and GAD-NSUD across a broad range of service settings. Regardless of the presence of SUD, nearly 50% of individuals with GAD received no treatment, with an approximate 2-year lag between onset and first treatment among those that received treatment for GAD. Similarly, we also found

no difference in the time lapsed from onset of GAD to first treatment, despite the increased severity and additional psychiatric comorbidity present in the GAD-SUD group. This is consistent with prior studies showing that, although psychiatric comorbidity and mental health–related disability are generally strong predictors of mental health service use,^{74,75} comorbidity with SUD may not significantly increase rates of treatment for mood and anxiety disorders.⁷⁶

Among those that sought treatment, individuals with GAD-SUD were as likely as those with GAD-NSUD to receive pharmacologic treatment for anxiety. This practice is consistent with evidence^{67,77,78} that medication for anxiety symptoms in individuals with comorbid SUD is efficacious.

The findings of this study should be interpreted in light of several limitations. First, because the NESARC sample only included civilian households and group quarters of populations 18 years and older, information was unavailable on adolescents or individuals in prison, groups that may be at increased risk for GAD and SUD. Second, the cross-sectional design of the NESARC limits elucidation of the impact of the risk of chronicity and disability in GAD and comorbid conditions conferred by diagnostic group. Third, the reliability of the GAD diagnosis was only fair, which may have attenuated the relationship between GAD diagnosis and other variables in the study. Thus, our results are conservative. Fourth, although our study included a broad range of risk factors, it is not fully comprehensive.

Despite these limitations, this study provides the most comprehensive information to date on the prevalence, risk factors, psychiatric comorbidity, clinical correlates, and treatment patterns among individuals suffering from GAD

with and without comorbid SUD. Our findings indicate that individuals with GAD-SUD constitute half of the lifetime prevalence of GAD and are associated with high overall vulnerability for additional psychopathology, particularly in the externalizing spectrum; higher disability; and higher use of alcohol and drugs to relieve anxiety symptoms. Future studies should investigate the existence of genetic, neuroimaging differences between GAD-SUD and GAD-NSUD and the impact of SUD in the longitudinal course and treatment patterns of GAD.

Disclosure of off-label usage: The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents that is outside US Food and Drug Administration–approved labeling has been presented in this article.

Author affiliations: New York State Psychiatric Institute, New York (Mss Alegria, Liu, and Davies and Drs Hasin, Nunes, and Blanco); Department of Epidemiology, Mailman School of Public Health (Dr Hasin) and Department of Psychiatry, College of Physicians and Surgeons (Drs Hasin, Nunes, and Blanco), Columbia University, New York, New York; and Laboratory of Epidemiology and Biometry, Division of Intramural Clinical and Biological Research, National Institute of Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), Bethesda, Maryland (Dr Grant).

Financial disclosure: Dr Blanco has received grant/research support from GlaxoSmithKline, Eli Lilly, and Pfizer. Mss Alegria, Liu, and Davies and Drs Hasin, Nunes, and Grant have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

Funding/support: The National Epidemiologic Survey on Alcohol and Related Conditions was sponsored by the NIAAA and was funded, in part, by the Intramural Program, NIAAA, NIH. This study was supported by NIH grants DA019606, DA020783, DA023200, and MH076051 (Dr Blanco); R01AA08159 and K05AA00161 (Dr Hasin); and K24 DA022412 (Dr Nunes); the American Foundation for Suicide Prevention (Dr Blanco); and the New York State Psychiatric Institute (Drs Blanco, Nunes, and Hasin).

Disclaimer: The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of any of the sponsoring organizations, the agencies, or the US government.

REFERENCES

- Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychol Med*. 2005;35(12):1747–1759.
- ESEMeD/MHEDEA 2000 Investigators. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. *Acta Psychiatr Scand*. 2004; 109(s420):21–27.
- Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. *Arch Gen Psychiatry*. 1994; 51(5):355–364.
- Ballenger JC, Davidson JR, Lecrubier Y, et al; International Consensus Group on Depression and Anxiety. Consensus statement on depression, anxiety, and oncology. *J Clin Psychiatry*. 2001;62(suppl 8):64–67.
- Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. *Depress Anxiety*. 2002;16(4):162–171.
- Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. *J Clin Psychiatry*. 2002;63(suppl 8):24–34.
- Baving L, Olbrich H. Anxiety in alcohol-dependent patients [in German]. *Fortschr Neurol Psychiatr*. 1996;64(3):83–89.
- Kushner MG, Abrams K, Borchardt C. The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. *Clin Psychol Rev*. 2000;20(2):149–171.
- Schuckit MA, Irwin M, Smith TL. One-year incidence rate of major depression and other psychiatric disorders in 239 alcoholic men. *Addiction*. 1994;89(4):441–445.
- Hesselbrock MN, Meyer RE, Keener JJ. Psychopathology in hospitalized alcoholics. *Arch Gen Psychiatry*. 1985;42(11):1050–1055.
- McEvoy PM, Shand F. The effect of comorbid substance use disorders on treatment outcome for anxiety disorders. *J Anxiety Disord*. 2008;22(6):1087–1098.
- Rounsaville BJ, Anton SF, Carroll K, et al. Psychiatric diagnoses of treatment-seeking cocaine abusers. *Arch Gen Psychiatry*. 1991;48(1):43–51.
- Rounsaville BJ, Dolinsky ZS, Babor TF, et al. Psychopathology as a predictor of treatment outcome in alcoholics. *Arch Gen Psychiatry*. 1987;44(6): 505–513.
- Swendsen JD, Merikangas KR. The comorbidity of depression and substance use disorders. *Clin Psychol Rev*. 2000;20(2):173–189.
- Conway KP, Compton W, Stinson FS, et al. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*. 2006;67(2):247–258.
- Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry*. 2004;61(8):807–816.
- Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62(6):617–627.
- Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. *Arch Gen Psychiatry*. 1997;54(4):313–321.
- Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. *JAMA*. 1990;264(19):2511–2518.
- Brady KT, Lydiard RB. The association of alcoholism and anxiety. *Psychiatr Q*. 1993;64(2):135–149.
- Compton WM 3rd, Cottler LB, Jacobs JL, et al. The role of psychiatric disorders in predicting drug dependence treatment outcomes. *Am J Psychiatry*. 2003;160(5):890–895.
- Schuckit MA, Hesselbrock V. Alcohol dependence and anxiety disorders: what is the relationship? *Am J Psychiatry*. 1994;151(12):1723–1734.
- Burns L, Teesson M. Alcohol use disorders comorbid with anxiety, depression and drug use disorders: findings from the Australian National Survey of Mental Health and Well Being. *Drug Alcohol Depend*. 2002;68(3): 299–307.
- Burns L, Teesson M, O'Neill K. The impact of comorbid anxiety and depression on alcohol treatment outcomes. *Addiction*. 2005;100(6):787–796.
- Oei TP, Loveday WA. Management of co-morbid anxiety and alcohol disorders: parallel treatment of disorders. *Drug Alcohol Rev*. 1997;16(3): 261–274.
- Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. *Am J Psychiatry*. 2005;162(6):1179–1187.
- de Graaf R, Bijl RV, Ten Have M, et al. Pathways to comorbidity: the transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study. *J Affect Disord*. 2004; 82(3):461–467.
- Marquenie LA, Schadé A, van Balkom AJ, et al. Origin of the comorbidity of anxiety disorders and alcohol dependence: findings of a general population study. *Eur Addict Res*. 2007;13(1):39–49.
- Kushner MG, Abrams K, Thurans P, et al. Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients. *Alcohol Clin Exp Res*. 2005;29(8):1432–1443.
- Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. *Am J Psychiatry*. 1990;147(6):685–695.
- Swendsen JD, Merikangas KR, Canino GJ, et al. The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. *Compr Psychiatry*. 1998;39(4):176–184.
- Grant BF, Dawson DA, Stinson FS, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. *Drug Alcohol Depend*. 2003;71(1):7–16.
- Grant B, Dawson D, Hasin D. *The Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV Version*. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2001.
- Grant BF, Harford TC, Dawson DA, et al. The Alcohol Use Disorder and Associated Disabilities Interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. *Drug Alcohol Depend*. 1995;39(1):37–44.
- Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, and disability of personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*. 2004;65(7):948–958.

36. Canino G, Bravo M, Ramírez R, et al. The Spanish Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability and concordance with clinical diagnoses in a Hispanic population. *J Stud Alcohol*. 1999;60(6):790–799.
37. Pull CB, Saunders JB, Mavreas V, et al. Concordance between ICD-10 alcohol and drug use disorder criteria and diagnoses as measured by the AUDADIS-ADR, CIDI and SCAN: results of a cross-national study. *Drug Alcohol Depend*. 1997;47(3):207–216.
38. Cottler LB, Grant BF, Blaine J, et al. Concordance of DSM-IV alcohol and drug use disorder criteria and diagnoses as measured by AUDADIS-ADR, CIDI and SCAN. *Drug Alcohol Depend*. 1997;47(3):195–205.
39. Grant BF, Stinson FS, Hasin DS, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*. 2005;66(10):1205–1215.
40. Compton WM, Conway KP, Stinson FS, et al. Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*. 2005;66(6):677–685.
41. Grant BF, Hasin DS, Stinson FS, et al. Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: results from the national epidemiologic survey on alcohol and related conditions. *J Psychiatr Res*. 2005;39(1):1–9.
42. Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatric disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry*. 2004; 61(11):1107–1115.
43. Hasin D, Samet S, Nunes E, et al. Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. *Am J Psychiatry*. 2006; 163(4):689–696.
44. Hasin DS, Trautman KD, Miele GM, et al. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. *Am J Psychiatry*. 1996;153(9):1195–1201.
45. Torrens M, Serrano D, Astals M, et al. Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. *Am J Psychiatry*. 2004; 161(7):1231–1237.
46. Chatterji S, Saunders JB, Vrstai R, et al. Reliability of the alcohol and drug modules of the Alcohol Use Disorder and Associated Disabilities Interview Schedule–Alcohol/Drug-Revised (AUDADIS-ADR): an international comparison. *Drug Alcohol Depend*. 1997;47(3):171–185.
47. Grant BF, Moore TC, Shepard J, et al. *Source and Accuracy Statement: Wave 1 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)*. Bethesda, MD: National Institute of Alcohol Abuse and Alcoholism; 2003.
48. Hasin D, Carpenter KM, McCloud S, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a clinical sample. *Drug Alcohol Depend*. 1997;44(2–3):133–141.
49. Nelson CB, Rehm J, Ustün TB, et al. Factor structures for DSM-IV substance disorder criteria endorsed by alcohol, cannabis, cocaine and opiate users: results from the WHO reliability and validity study. *Addiction*. 1999;94(6):843–855.
50. Hasin D, Grant BF, Cottler L, et al. Nosological comparisons of alcohol and drug diagnoses: a multisite, multi-instrument international study. *Drug Alcohol Depend*. 1997;47(3):217–226.
51. Hasin D, Li Q, Mccloud S, et al. Agreement between DSM-III, DSM-III-R, DSM-IV and ICD-10 alcohol diagnoses in US community-sample heavy drinkers. *Addiction*. 1996;91(10):1517–1527.
52. Hasin D, Van Rossem R, McCloud S, et al. Alcohol dependence and abuse diagnoses: validity in community sample heavy drinkers. *Alcohol Clin Exp Res*. 1997;21(2):213–219.
53. Hasin D, Paykin A. Alcohol dependence and abuse diagnoses: concurrent validity in a nationally representative sample. *Alcohol Clin Exp Res*. 1999;23(1):144–150.
54. Muthén BO, Grant B, Hasin D. The dimensionality of alcohol abuse and dependence: factor analysis of DSM-III-R and proposed DSM-IV criteria in the 1988 National Health Interview Survey. *Addiction*. 1993;88(8): 1079–1090.
55. Grant BF, Stinson FS, Dawson DA, et al. Co-occurrence of DSM-IV personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Compr Psychiatry*. 2005;46(1):1–5.
56. Moffitt TE, Caspi A, Harrington H, et al. Generalized anxiety disorder and depression: childhood risk factors in a birth cohort followed to age 32. *Psychol Med*. 2007;37(3):441–452.
57. Kendler KS, Davis CG, Kessler RC. The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. *Br J Psychiatry*. 1997;170(6):541–548.
58. Kendler KS, Hettema JM, Butera F, et al. Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety. *Arch Gen Psychiatry*. 2003;60(8): 789–796.
59. Finlay-Jones R, Brown GW. Types of stressful life event and the onset of anxiety and depressive disorders. *Psychol Med*. 1981;11(4):803–815.
60. Holmes TH, Rahe RH. The Social Readjustment Rating Scale. *J Psychosom Res*. 1967;11(2):213–218.
61. Ware JE, Turner-Bowker DM, Gandek B. *How to Score Version 2 of the SF-12 Health Survey*. Lincoln, RI: Quality Metrics; 2002.
62. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care*. 1996;34(3):220–233.
63. *Software for Survey Data Analysis (SUDAAN)* [computer program]. Version 9.0. Research Triangle Park, NC: Research Triangle Institute; 2002.
64. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62(6):593–602.
65. Blanco C, Alderson D, Ogburn E, et al. Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991–1992 and 2001–2002. *Drug Alcohol Depend*. 2007;90(2–3):252–260.
66. Nunes EV, McGrath PJ, Quitkin FM. Treating anxiety in patients with alcoholism. *J Clin Psychiatry*. 1995;56(suppl 2):3–9.
67. Krueger RF. The structure of common mental disorders. *Arch Gen Psychiatry*. 1999;56(10):921–926.
68. Kessler RC, Rubinow DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. *Psychol Med*. 1997;27(5):1079–1089.
69. Bauer MS, Altshuler L, Evans DR, et al. VA Cooperative Study #430 Team. Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. *J Affect Disord*. 2005;85(3):301–315.
70. Oquendo MA, Currier D, Liu S-M, et al. Increased risk for suicidal behavior in comorbid bipolar disorder and alcohol use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clin Psychiatry*. 2010;71(7):902–909.
71. Vieta E, Colom F, Martínez-Arán A, et al. Bipolar II disorder and comorbidity. *Compr Psychiatry*. 2000;41(5):339–343.
72. Weiss RD, Ostacher MJ, Otto MW, et al. STEP-BD Investigators. Does recovery from substance use disorder matter in patients with bipolar disorder? *J Clin Psychiatry*. 2005;66(6):730–735, quiz 808–809.
73. Bolton JM, Robinson J, Sareen J. Self-medication of mood disorders with alcohol and drugs in the National Epidemiologic Survey on Alcohol and Related Conditions. *J Affect Disord*. 2009;115(3):367–375.
74. Bland RC, Newman SC, Orn H. Help-seeking for psychiatric disorders. *Can J Psychiatry*. 1997;42(9):935–942.
75. Katz SJ, Kessler RC, Frank RG, et al. The use of outpatient mental health services in the United States and Ontario: the impact of mental morbidity and perceived need for care. *Am J Public Health*. 1997;87(7):1136–1143.
76. Mojtabai R, Olfson M, Mechanic D. Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. *Arch Gen Psychiatry*. 2002;59(1):77–84.
77. Frances RJ, Borg L. The treatment of anxiety in patients with alcoholism. *J Clin Psychiatry*. 1993;54:37–43.
78. Klein DF. Delineation of two drug-responsive anxiety syndromes. *Psychopharmacologia*. 1964;5(6):397–408.

For the CME Posttest for this article, see pages 1252–1253.
